News | Proton Therapy | June 14, 2019

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

Streamlined quality assurance process will allow Netherlands center to treat more patients per day

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

June 14, 2019 – IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and clinically implemented a novel automated treatment log-based patient quality assurance (QA) approach for proton therapy. This enables them to reduce the time needed for the in-beam measurement-based conventional patient QA.

With this new approach, the center is now able to streamline and reduce the QA time per patient, extract more clinically relevant information from the QA data and establish continuous quality control of the treatment throughout the course. Furthermore, this will allow them to reduce the time to continue treatment course with adapted plans, when needed, and make a step towards supporting online adaptive workflows.

This new automated patient QA approach combines several open source projects: CAPTAIN, an automatic workflow manager using web-technology; a DICOM picture archiving and communication system (PACS) database (Orthanc) providing an interface with the treatment planning system (TPS); computation routines from open-REGGUI and others, developed at UMCG; and a Monte Carlo proton dose engine (MCsquare).

CAPTAIN, open-REGGUI and MCsquare are open-source research tools supported by the openPath initiative, which is aimed at researchers, medical physicists and clinicians to accelerate research. It is the first time that a center has applied the extensive internal QA validation of UMCG to use the open source software platform in the clinic.

Prof. Stefan Both, head of physics at UMCG, commented, “Thanks to the support of IBA and the OpenPath platform, we managed to develop and implement an automated patient QA process that will allow us to considerably reduce the time to perform patient QA operations from about 45 minutes to 5 minutes. This means we have today the capacity to treat [an] additional 1 to 2 fractions per day, shorten [by] two days the time from simulation to treatment delivery and explore adaptive proton therapy protocols to maximize the clinical potential of the proton treatment beam.”

For more information: www.iba-worldwide.com

Related Content

Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
Lung cancer patients who are inactive prior to chemoradiation are less likely to tolerate treatment and more likely to see their cancer return
News | Lung Cancer | January 08, 2020
January 8, 2020 — Numerous ...
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected